Qin H. Resveratrol: A promising agent in targeting senescent cancer-associated fibroblasts to inhibit pancreatic cancer progression. World J Gastrointest Oncol 2025; 17(7): 105034 [DOI: 10.4251/wjgo.v17.i7.105034]
Corresponding Author of This Article
Hao Qin, PhD, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. haoqin@bjmu.edu.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jul 15, 2025; 17(7): 105034 Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.105034
Resveratrol: A promising agent in targeting senescent cancer-associated fibroblasts to inhibit pancreatic cancer progression
Hao Qin
Hao Qin, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Author contributions: Qin H was responsible for the study’s conception, manuscript writing and editing, and final approval.
Supported by National Natural Science Foundation of China, No. 82304151.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hao Qin, PhD, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. haoqin@bjmu.edu.cn
Received: January 10, 2025 Revised: February 19, 2025 Accepted: February 26, 2025 Published online: July 15, 2025 Processing time: 186 Days and 6 Hours
Abstract
Pancreatic cancer is a highly aggressive malignancy with a poor prognosis and limited therapeutic options. The tumor microenvironment (TME), including cancer-associated fibroblasts (CAFs), plays a pivotal role in tumor progression and therapy resistance. Senescent CAFs, which exhibit a senescence-associated secretory phenotype (SASP), further exacerbate cancer growth through inflammatory cytokine secretion. This editorial highlights a study by Jiang et al, which investigates the potential of resveratrol, a natural polyphenolic compound, in targeting senescent CAFs to inhibit pancreatic cancer progression. The study demonstrates that resveratrol reduces senescent CAFs and downregulates SASP factors, thereby disrupting the pro-tumorigenic activities of these cells. Resveratrol’s ability to modulate the TME, induce apoptosis in pancreatic cancer cells, and inhibit metastasis underscores its potential as an adjunctive therapy. This research offers promising insights into novel strategies for improving therapeutic outcomes in pancreatic cancer by targeting the TME and senescent CAFs.
Core Tip: Pancreatic cancer remains a challenging disease with limited treatment options, largely due to the tumor microenvironment (TME) and its cancer-associated fibroblasts (CAFs). Senescent CAFs, through their senescence-associated secretory phenotype (SASP), contribute to tumor progression. Recent studies have explored the potential of resveratrol, a natural polyphenolic compound, to target these senescent CAFs. Resveratrol reduces the number of senescent CAFs, downregulates SASP factors, and disrupts tumor-promoting interactions in the TME. These findings suggest that resveratrol could serve as an effective adjunctive therapy for pancreatic cancer by modulating the TME and inhibiting cancer cell proliferation and metastasis.
